Literature DB >> 8879889

Changing antipsychotic medication: guidelines on the transition to treatment with risperidone. The Consensus Study Group on Risperidone Dosing.

R L Borison1.   

Abstract

When treating patients with psychoses, clinicians must often consider changing their treatment from one antipsychotic agent to another. The transition may be necessary because the patient experiences serious side effects or because the existing therapy no longer controls the patient's symptoms. A principal problem in changing antipsychotic agents is the potential for withdrawal symptoms resulting from discontinuation of the existing therapy. These syndromes can manifest as reemergence or worsening of psychosis, rebound or unmasked dyskinesia, and cholinergic-rebound symptoms. Withdrawal signs and symptoms may include insomnia, nausea, vomiting, anxiety, and agitation. When switching a patient to the new antipsychotic agent risperidone, the clinician can keep withdrawal symptoms to a minimum by considering the patient's clinical history and current status. For some patients, abrupt withdrawal of the current antipsychotic may be possible. For others, the dose of the previous medication must be gradually reduced before risperidone is initiated. In many cases, the transition is best made by overlapping the existing therapy and risperidone.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8879889     DOI: 10.1016/s0149-2918(96)80211-6

Source DB:  PubMed          Journal:  Clin Ther        ISSN: 0149-2918            Impact factor:   3.393


  8 in total

Review 1.  Anticholinergic side-effects of drugs in elderly people.

Authors:  J Mintzer; A Burns
Journal:  J R Soc Med       Date:  2000-09       Impact factor: 5.344

2.  Use of healthcare services by patients treated with risperidone versus conventional antipsychotic agents.

Authors:  Frank Gianfrancesco; Michael B Durkin; Ramy Mahmoud; Ruey-Hua Wang
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

Review 3.  Methods for claims-based pharmacoeconomic studies in psychosis.

Authors:  Frank Gianfrancesco; Ruey-Hua Wang; Ramy Mahmoud; Richard White
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

Review 4.  Switching between second-generation antipsychotics: why and how?

Authors:  Monika Edlinger; Susanne Baumgartner; Nadja Eltanaihi-Furtmüller; Martina Hummer; W Wolfgang Fleischhacker
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

Review 5.  Withdrawal symptoms and rebound syndromes associated with switching and discontinuing atypical antipsychotics: theoretical background and practical recommendations.

Authors:  Anja Cerovecki; Richard Musil; Ansgar Klimke; Florian Seemüller; Ekkehard Haen; Rebecca Schennach; Kai-Uwe Kühn; Hans-Peter Volz; Michael Riedel
Journal:  CNS Drugs       Date:  2013-07       Impact factor: 5.749

Review 6.  A risk-benefit assessment of risperidone for the treatment of behavioural and psychological symptoms in dementia.

Authors:  M Zaudig
Journal:  Drug Saf       Date:  2000-09       Impact factor: 5.606

Review 7.  Practical issues with amisulpride in the management of patients with schizophrenia.

Authors:  Luca Pani; José M Villagrán; Vassilis P Kontaxakis; Köksal Alptekin
Journal:  Clin Drug Investig       Date:  2008       Impact factor: 2.859

8.  Assessment of strategies for switching patients from olanzapine to risperidone: a randomized, open-label, rater-blinded study.

Authors:  Rohan Ganguli; Jaspreet S Brar; Ramy Mahmoud; Sally A Berry; Gahan J Pandina
Journal:  BMC Med       Date:  2008-06-30       Impact factor: 8.775

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.